CRESCENT BIOPHARMA, INC.

Regulatory Filings • Oct 5, 2017

CORRESP 1 filename1.htm

October 5, 2017

VIA EDGAR

Mr. Christopher Edwards

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

*Re: GlycoMimetics, Inc. (the “ Registrant ”) Registration Statement on Form S-3, File No. 333-220697*

*Acceleration Request*

*Requested Date: Friday, October 6, 2017*

*Requested Time: 4:00 p.m. Eastern Time*

Dear Mr. Edwards:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “ *Registrant ”) hereby requests that the Securities and Exchange Commission (the “ Commission ”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-220697) (the “ Registration Statement ”) to become effective on Friday, October 6, 2017, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable, or at such later time as the Registrant may orally request via telephone call to the staff (the “ Staff*** ”).

Once the Registration Statement has been declared effective, please orally confirm that event with Katie Kazem of Cooley LLP, counsel to the Registrant, at (703) 456-8043, or in her absence, Mark Ballantyne at (703) 456-8084.

	GLYCOMIMETICS, INC.
	By:	/s/ Brian M. Hahn
		Brian M. Hahn
		Chief Financial Officer
cc:	Brent B. Siler, Cooley LLP
	Brian F. Leaf, Cooley LLP

SEQ.=1,FOLIO='',FILE='C:\JMS\109763\17-22626-4\task8594578\22626-4-bg.htm',USER='109763',CD='Oct 6 00:23 2017'